Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.45 |
| ▸ | CLK1 | P49759 | 3/20 | 0.45 |
| ▸ | CLK2 | P49760 | 3/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.44 |
| ▸ | CLK3 | P49761 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757421 | 0.84 | NPC1 (0.47) | ADORA2APDE10ACLK4KDM4ETDP1 | |
| SCHEMBL5758176 | 0.83 | PDE10A (0.53) | ADORA2APDE10AKDM4EL3MBTL1MAPT | |
| SCHEMBL5757793 | 0.81 | ALDH1A1 (0.45) | ADORA2ACLK4DYRK1ACLK1CLK2 | |
| SCHEMBL5758452 | 0.78 | HPGDS (0.57) | PDE10ANPY5R | |
| SCHEMBL5756970 | 0.76 | SSTR3 (0.42) | ADORA2APDE10ANPY5RSLC6A4 | |
| SCHEMBL5755506 | 0.75 | PDE10A (0.41) | ADORA2APDE10ANPY5R | |
| SCHEMBL5759555 | 0.75 | HPGDS (0.53) | PDE10ANPY5RSLC6A4 | |
| SCHEMBL5758953 | 0.75 | HPGDS (0.56) | ADORA2APDE10ANPY5RSLC6A4 | |
| SCHEMBL5759979 | 0.75 | NPY5R (0.51) | ADORA2ANPY5R | |
| SCHEMBL5756347 | 0.75 | NPY5R (0.47) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | ADORA2A 3924/4885PDE10A 2803/4885CLK4 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.